

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

25 March 2022 | News

The X-Cancer's investigator-led trial of SAR-bisPSMA in known or suspected prostate cancer (X-Calibur) is a Phase I/II IIT in up to 150 patients at the Urology Cancer Center and GU Research Network (GURN)



Australia's Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology announced that an investigator-initiated trial (IIT) will commence shortly in the US investigating ^{64}Cu SAR-bisPSMA in prostate cancer (NCT05286840).

The X-Cancer's investigator-led trial of SAR-bisPSMA in known or suspected prostate cancer (X-Calibur) is a Phase I/II IIT in up to 150 patients at the Urology Cancer Center and GU Research Network (GURN) in Omaha, Nebraska, sponsored by Dr Luke Nordquist. It will investigate a broad spectrum of prostate cancer patients by imaging with ^{64}Cu -SAR-bisPSMA on the day of administration and at later timepoints. The X-Calibur trial will be assessing the safety of ^{64}Cu SAR-bisPSMA as well as looking at the impact of the product on staging and clinical management of participants with prostate cancer.